CRISPR Therapeutics CRSP Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's increase (decrease) in accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's increase (decrease) in accounts receivable?
- CRISPR Therapeutics (CRSP) reported increase (decrease) in accounts receivable of -$0 in Q1 2026.
- How has CRISPR Therapeutics's increase (decrease) in accounts receivable changed year-over-year?
- CRISPR Therapeutics's increase (decrease) in accounts receivable increased by 100.0% year-over-year, from -$25M to -$0.
- What is the long-term trend for CRISPR Therapeutics's increase (decrease) in accounts receivable?
- Over 2 years (2021 to 2023), CRISPR Therapeutics's increase (decrease) in accounts receivable has grown at a 3424.5% compound annual growth rate (CAGR), from $161K to $200M.